|
|||||
|
|
Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer |
|
| Authors: | Zhi-jie Wang Tong-tong An Tony Mok Lu Yang Hua Bai Jun Zhao Jian-chun Duan Mei-na Wu Yu-yan Wang Ping-ping Li Hong Sun Ping Yang Jie Wang |
| Institution: | Zhi-jie Wang1,2,Tong-tong An1*,Tony Mok4,Lu Yang1,Hua Bai1,Jun Zhao1,Jian-chun Duan1,2 Mei-na Wu1,Yu-yan Wang1,Ping-ping Li1,3,Hong Sun3,Ping Yang5,Jie Wang1,2 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),2Department of Thoracic Medical Oncology,3Department of Integrative Medicine,Peking University School of Oncology,Beijing Cancer Hospital & Institute,Beijing,China,4Department of Clinical Oncology,Chinese University of Hong Kong,Hong Kong,... |
| Abstract: | Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group). Methods: The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end... |
| Keywords: | EGFR tyrosine kinase inhibitor Maintenance therapy Non-small-cell lung cancer |
| 本文献已被 CNKI SpringerLink 等数据库收录！ | |